UTI pathogen

Boosting the Body’s Natural Ability to Fight Urinary Tract Infections

Urinary tract infections (UTIs) are common, and widespread antibiotic resistance has led to urgent calls for new ways to combat them. Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that an experimental drug that stabilizes a protein called HIF-1alpha protects human bladder cells and mice against a major UTI pathogen. The drug might eventually provide a therapeutic alternative or complement to standard antibiotic treatment.

Abundance of bacteria in the opening of a mouse bladder (center) is...
Abundance of bacteria in the opening of a mouse bladder (center) is significantly reduced in the treated bladder (right).
Source: UC San Diego

HIF-1alpha is known to influence the innate immune response, the body’s first line of defense against intruding pathogens. Like many regulator proteins, HIF-1alpha is relatively short-lived. To increase HIF-1alpha levels, researchers have developed drugs that delay its breakdown. This same pathway has been the target for drugs now in advanced clinical trials for treatment of anemia.

In this study, Victor Nizet, MD, professor of pediatrics and pharmacy, and colleagues explored the use of HIF-1alpha-stabilizing drugs to boost the innate immune response to uropathogenic E.coli (UPEC) bacteria, a major cause of UTIs. In healthy human urinary tract cells, treatment with the drugs increased HIF-1alpha levels. Such cells were then more resistant to UPEC attachment, invasion and killing than human urinary tract cells with normal HIF-1alpha levels.

Using a mouse model of UTI, the researchers showed that administration of HIF-1alpha stabilizers directly into the bladder protected against UPEC infection. They also found that invasion of bladder cells, a critical early step in the infection process, was reduced in treated mice compared to untreated mice.

To verify the importance of HIF-1alpha in the defense against UPEC infection, the researchers studied mice with reduced HIF-1alpha levels. Exposed to UPEC, these mice were more susceptible to bladder infection, and pre-treatment with HIF-1alpha stabilizers made no difference. This demonstrates that the drugs combat UTIs through their effect on HIF-1alpha.

Finally, the researchers examined whether treatment with HIF-1alpha stabilizers would be beneficial against an established UTI. To do this, they infected mice with UPEC first and then administered the drugs into the bladder six hours later. The treated mice had a more than 10-fold reduction in bladder colonization with the bacteria, demonstrating that HIF-1alpha stabilization is beneficial even after the initial infection.

“The ultimate goal of this research will be to advance HIF-1alpha stabilizers toward clinical trials in humans, using versions of the drug that can be taken orally and reach the urinary tract,” Nizet said.


Reference:
Co-authors include Ann E. Lin, Federico C. Beasley, Joshua Olson, and Nadia Keller, UC San Diego; Robert A. Shalwitz, Aerpio Therapeutics; Thomas J. Hannan, and Scott J. Hultgren, Washington University.


Source: UC San Diego

23.06.2015

Read all latest stories

Related articles

Photo

Alternative therapy

Potent nanodrug combast antibiotic-resistant infections

A research team led by University of Arkansas chemist Jingyi Chen and University of Arkansas for Medical Sciences microbiologist Mark Smeltzer has developed an alternative therapeutic approach to…

Photo

Stopping malaria in its tracks

A new drug acts as a roadblock for malaria, curing mice of established infection, according to a study in The Journal of Experimental Medicine. Treatment was not associated with obvious side effects,…

Photo

Antimicrobial stewardship

A diagnostic marker reduces antibiotics use

Since 2009, as part of diagnostic and antimicrobial stewardship strategies, Hampshire Hospitals National Health Service (NHS) Trust has used serum procalcitonin (PCT) – an innovative and highly…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
DiaSys Diagnostic Systems - InnovaStar

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Hamamatsu Photonics – NanoZoomer S360

Scanner

Hamamatsu Photonics – NanoZoomer S360

Hamamatsu Photonics Deutschland GmbH